Introduction mechanical stretch [10] . Stretch-activated ion channels were originally identified in chick skeletal myocytes by Haemodynamic forces associated with blood flow play use of the patch-clamp technique. They are involved a crucial role in the acute regulation of vascular tone in the mechanotransduction of various tissues in verand long-term changes of vascular structure and tebrates and non-vertebrates [11 ] . Pathophysioremodelling [1, 2] . Alterations in endothelial function logically a dysfunction of mechanosensitive ion chanappear to be involved in the disturbed vasoregulation nels have been reported to be involved in stretchin hypertension and in the development of atherosclerinduced arrhythmias [12 ] and in muscular dystrophy otic lesions of the vessel wall [2] . Located at the [13] . These specialized ion channels are sensitive to interface between blood and vessel wall, the endothelium is directly subjected to haemodynamic forces changes in membrane tension or stretch which can be associated with blood flow and responds to haemo-induced under experimental conditions by suction dynamic stimulation with the secretion of vasoactive applied to the rear of the patch pipette. The activation mediators. Increases in blood flow induce a vasodil-of the channels shows a graded increase of channel ation which depends on an intact endothelium and is activity with respect to the degree of membrane stretch mediated by endothelium-derived factors like nitric elicited by different strengths of pipette suction. The oxide (NO) or prostacyclin ( PGI 2 ). Flow-dependent electrophysiological properties of the channel, i.e. ion vasodilatation is an important protective mechanism selectivity and channel conductance, remain unaffected to avoid damage of the vessel wall by frictional wall by membrane stretch. Endothelial stretch-activated shear stresses associated with flow. channels have a channel conductance between 25 and The mechanism by which the endothelium senses 45 pS and are impermeable for anions and permeable flow and the associated haemodynamic forces and for mono-and divalent cations [9, 14, 15] . The channel transforms them into biochemical signals ultimately permeability for Ca2+ ions is 3-4 times lower than for leading to the secretion of endothelial mediators has monovalent cations e.g. K+ and Na+. However, indirbeen incompletely characterized so far. Activation of ect evidence showed that due to the large inwardly ion channels and changes in intracellular calcium directed electrochemical gradient for Ca2+ ions an homeostasis are involved in the acute response of the activation of the stretch-activated channels leads to a endothelium to mechanical stimulation [3 ] . This is sufficient Ca2+ influx into the endothelial cell and demonstrated by the observation that the flow-induced increases the intracellular Ca2+ concentration [14, 16 ] . endothelium-dependent vasodilatation in perfused Stretch-activated ion channels are blocked by gadolinarteries depends on the activity of K+ channels [4 ] ium, a trivalent lanthanide, in concentrations of less and involves an increase in intracellular Ca2+ concenthan 30 mmol/l. tration [5 ] . It should be mentioned that in contrast to Furthermore, two K+-selective mechanosensitive ion previous reports [6, 7] the Ca2+-dependent phase of channels have been observed in endothelial cells. An flow-induced NO production was recently reported to endothelial stretch-activated K+ channel (SAC K ) has be abolished in perfused isolated conduit arteries of been identified in freshly isolated rat aortic endothelial the rabbit after restoring the assumed in vivo length of cells [17] . This channel had a mean channel conductthe arteries [8 ] .
ance in cell-attached patches of 70 pS and was selectively permeable for K+ ions with a permeability ratio ation of the endothelium. Correspondingly, endothelial on the cell potential and could therefore impair endothelial function. Thus, the precise function of the hyperpolarization measured by whole cell current recording or fluorescence dyes has been shown to be pressure-activated channel remains to be determined by use of specific channel blockers. The channel was elicited by shear stress in bovine aortic and pulmonary endothelial cells [19, 20] . Both signals, an increase in almost exclusively observed in intact tissue preparations, rarely in freshly isolated endothelial cells, but intracellular Ca2+ concentration and cell hyperpolarization are important stimulators of Ca2+ dependent not in cultured endothelial cells. This emphasizes the importance of experiments using whole tissue prepara-NO-production in endothelial cells [6, 21] . Thus stretch-activated cation channels can act as mechano-tions where the target cell is situated in its natural environment. sensors and transform mechanical stimulation into an intracellular signal leading to a vasodilatory response ( Figure 1 ).
Mechanosensitive channels in hypertension
The mechanism by which mechanosensitive forces may control the channel gating process is not well understood. Submembraneous cytoskeletal structures In human and experimental hypertension an endothelthat integrate tension from a wider area of membrane ial dysfunction has been described. The increased vasmight be involved in channel gating. This was indicated cular tone in hypertension is in part due to an by the observation that disruption of the cytoskeleton imbalance in the secretion of vasodilating and vasoconby specific drugs alters or abolishes the mechanosensi-stricting mediators by the endothelium [23] . Also, the tivity of the channels [3 ] . endothelial response to haemodynamic stimulation has been reported to be impaired in hypertension as indicated by a decreased flow-induced endotheliumPressure-activated channels dependent vasodilatation in spontaneously hypertensive rats compared to normotensive Wistar-Kyoto rats [24] . In adult spontaneously hypertensive rats and in A new type of mechanosensitive ion channels has been identified in the endothelium of intact tissue slices from rats with renovascular hypertension (2K1C ) a more than twofold increase of the density of the SAC K and rat aorta and mesenteric artery [22] . The channel is activated when pressure is applied to the cell membrane the pressure-activated channel was found [22 ] proving that mechanosensitive channels are regulated in the via the patch pipette and not by pipette suction. The pressure-activated channel responds to increases of presence of altered haemodynamic forces. Channel upregulation and associated hyperpolarization by pressure with a graded increase in channel activity. This channel is permeable to monovalent cations and SAC K as well as the increased Ca2+ influx through the pressure-activated channel would lead to an enhanced Ca2+ ions. The Ca2+ influx through the pressureactivated channel is sufficient to activate neighboring vasodilatory response to haemodynamic stimulation.
However, it cannot be excluded that coactivation of Ca2+ dependent maxi K+ channels. However, also a co-activation of Ca2+ dependent non-selective cation depolarizing non-selective cation channels by pressureactivated channels, as stated above, would impair channels was observed which have a depolarizing effect However, this report will focus on recent findings by several other important aspects of the renal biology of amylin in the rat. Firstly, in experiments employing in our group which indicate that amylin acts in the kidney probably via a specific G-protein coupled receptor [3] . vivo labelling techniques with [125I ] rat amylin, using high-resolution light-microscopy and emulsion autoraThese effects of amylin have potential implications for various pathological conditions including hypertension diography, we have demonstrated that amylin binds to proximal tubules rather than distal tubules, coland the renal response to injury. These findings are of particular interest since the amylin analogue, pramlin-lecting ducts, or the interstitium [10] . Secondly, in micropuncture experiments, amylin, when introduced tide, is now in phase III clinical trials as an agent to control postprandial hyperglycaemia in diabetes [4] . from the peritubular but not the luminal side of the proximal tubules, significantly stimulated sodium/ water reabsorption by 29%. This effect was blocked by
Amylin receptors
the competitive inhibitor of the sodium/hydrogen exchanger, ethyl isopropyl amiloride [10] . Amylin, in High-affinity amylin binding sites have been detected these experiments, was demonstrated to have similar in both the kidney [3 ] and certain regions of the central efficacy to powerful pressor agents such as angiotensin nervous system [5 ] . Using in vitro autoradiographic II and endothelin. Furthermore, when the amylin techniques, we have described high-affinity sites of receptor antagonist, the peptide analogue AC187, was amylin binding ( Kd~1 nM ) in the rat renal cortex introduced intravenously, sodium/water reabsorption [3 ] . The pharmacological characteristics of these bind-was decreased by 22%, suggesting inhibition of the ing sites, as determined by the pattern of inhibition effects of endogenous amylin and therefore a role for using peptide antagonists, was very similar to those endogenous amylin in salt homeostasis. We have previously described in the rat brain [5, 6 ] . Amylin is reported that amylin introduced into rats [3 ] and a member of the same homologous group of peptides human volunteers [11] stimulated an acute increase in as calcitonin, adrenomedullin and calcitonin gene-plasma renin activity. The exact mechanism by which related peptide [1] . Thus far, the calcitonin (CTR), amylin stimulates plasma renin activity is not resolved adrenomedullin ( ADR) and CGRP receptors have and may involve both direct and indirect pathways, been cloned [7, 8] . From the deduced sequences, these including the activation of adenylate cyclase, a known receptors are members of a subclass of receptors which stimulator of renin secretion. traverse the membrane seven times and form an active ternary complex with G-proteins. These complexes represent the first step in the mechanism of signal amplification and activate or inhibit second-messenger Amylin as a mitogenic factor systems such as adenylyl cyclase. We have found that the hydrolysis-resistant analogue of GTP, GTPcS, A significant and related finding is that amylin stimuinhibits amylin binding by 92% to the renal cortex, lates the proliferation of primary cultures of epithelial providing pharmacological evidence that the amylin cells isolated from proximal tubules [10] . It is as potent receptor is itself a member of that same group of as epidermal growth factor in this regard. This proliferreceptors [3] . ative effect is inhibited by the same peptide antagonists Of importance in these experiments is the difference that inhibit binding [10 ] . Thus this effect is most between binding affinities as determined using autora-probably mediated by the amylin receptor located on diography of tissue sections (nM range), compared the peritubular, basolateral side of the proximal epithewith the binding constant determined in membrane lial cells, and involves the activation of the sodium/ preparations of the nucleus accumbens of the basal hydrogen antiporter oriented on the luminal surface. forebrain, which is 28 pM [6 ] . This difference, which Amylin has no significant effect on vascular smoothwe believe will be reflected also in the binding charac-muscle cell proliferation. However, the mitogenic teristics of the renal cortical sites, suggests that recep-effects of amylin have been reported in other cell types tors are subsaturated within the average physiological such as human endothelial cells of umbilical origin and plasma concentration of amylin. This is relevant since osteoblasts [12, 13] . it would suggest that functions in the kidney and brain would respond in the physiological and pathophysiological range of plasma amylin concentrations. Plasma amylin levels are elevated from an average concentra-Amylin and hypertension tion of less than 10 pM in normal individuals, to around 50-100 pM in hypertensive subjects [9] and up In the insulin resistance syndrome (syndrome X ) there to 400 pM in certain animal models of obesity and is a constellation of clinical and biochemical features hypertension [1] .
including hypertension, glucose intolerance, obesity, and dyslipidaemia [14] . Although hyperinsulinaemia
Amylin's actions in the kidney is commonly observed in this syndrome, the underlying pathogenic mechanism to explain the link between hypertension and glucose intolerance remains Besides the novel finding of high-affinity binding sites for amylin in the renal cortex, we have discovered unknown. It has been postulated that amylin, which influences both kidney functions and carbohydrate References metabolism, could be the elusive link [14, Phosphorus plays a critical role in cellular metabolism concentrations. The effects of growth hormone, insulin, [1 ] . Phosphorus is an important component of the cell and IGF are on other metabolic processes such as membrane phospholipids; it plays an exceptionally anabolism, glucose homeostasis, or cellular growth. It important role in intermediary and energy metabolism; would be biologically advantageous for an organism the role of phosphorus in signal transduction and its to possess a factor or a hormone that would specifically role in the activation or deactivation of various molec-respond to alterations in serum or extracellular fluid ules, usually proteins, by phosphorylation and dephos-phosphate concentrations without responding to phorylation is well known; finally, phosphorus is an changes, in calcium or or other signals. important component of both RNA and DNA.
There are several lines of evidence suggesting that a Clearly, perturbations that alter phosphorus concentra-factor which specifically regulates phosphorus concentions in the body will have significant biochemical and trations might exist in vivo. This notion comes from clinical consequences. Some of the clinical problems the study of diseases such as tumour-induced osteomaassociated with hypophosphataemia include osteoma-lacia, the epidermal nevus syndrome and X-linked lacia and rickets, rhabdomyolysis, and cardiomyopa-hypophosphataemic rickets (and the Hyp mouse homothy. High phosphorus concentrations, such as occur in logue of the latter condition). Patients with these renal failure, induce secondary hyperparathyroidism diseases develop hypophosphataemia and osteomalacia and attendant complications. [3] [4] [5] [6] [7] [8] [9] . Previous work had shown that epidermal nevi A normal human ingests about 1-1.5 g of phos-and certain tumours might elaborate a factor(s) capphorus in the diet per day [1 ] . Approximately 75% of able of inhibiting renal phosphate transport [7, 8] . what is ingested is absorbed in the intestine, enters the Recently, Cai et al. studied a patient with tumourextracellular fluid pool, and equilibrates between bone associated osteomalacia due to a haemangiopericytoma and serum. About 85% of total body phosphorus is [3] , and showed that a heretofore unrecognized factor, present in bone as hydroxyapatite. Serum inorganic 'phosphatonin', is elaborated by haemangiopericytoma phosphorus is filtered by the glomerulus, and about cells. The patient had a recurrent soft-tissue tum-80% of the filtered load is reabsorbed, mostly along our associated with hypophosphataemia, a reduced the proximal nephron [2] . Thus, the kidney plays an TMP/GFR, low 1,25-dihydroxyvitamin D concenexceptionally important role in regulating phosphorus trations, normal parathyroid hormone (PTH ) and balance.
parathyroid-hormone-related peptide (PTH-RP) Normally, shortly after the ingestion of a meal, there concentrations, and osteomalacia. Removal of the are large, influxes of calcium and phosphorus into the tumour on two occasions resulted in a complete resobody. The resulting elevation of the calcium-phosphate lution of biochemical and clinical defects. The tumour, product favours the precipitation of calcium and phoswhich on histology was a haemangiopericytoma, was phate as salts in tissues. One of the reasons why removed and cells were cultured to determine if they calcium and phosphate do not precipitate in the extrawere secreting a novel substance capable of inhibiting cellular fluid and soft tissue is that the kidney efficiently renal phosphate transport. excretes excess phosphate by hormonally regulated Medium conditioned by tumour cells inhibited the processes. Several hormones and factors such as parasodium-dependent uptake of phosphate in opossum thyroid hormone, 1,25-dihydroxyvitamin D, growth kidney (OK ) cells (a model of cultured proximal hormone, insulin, and insulin-like growth factors alter tubular cells). Control RPMI medium, RPMI medium renal phosphate reabsorption. However, these horthat had been exposed to Chinese hamster ovary mones and factors, are not solely involved in the regulation of phosphorus concentrations. For example, (CHO) cells, did not inhibit phosphate uptake. parathyroid hormone and 1,25-dihydroxyvitamin D Parathyroid hormone, as expected, inhibited phosphate are also responsible for the control of serum calcium transport. The effect of the tumour cell conditioned medium was specific for phosphate, inasmuch that Correspondence and offprint requests to: Rajiv Kumar, Ruth and only phosphate transport was inhibited in OK cells, were not. The tumour cell conditioned medium inhib-ited phosphate transport in OK cells without altering with X-linked hypophosphataemic rickets suggests that tumour-induced osteomalacia and the former condicAMP concentrations within the cell. This suggested that the factor present in tumour conditioned media tions may be related [5, 6 ] . Meyer et al. showed with parabiosis experiments that Hyp mice with hypophoswas not parathyroid hormone. Parathyroid hormone inhibited phosphate uptake, and as expected increased phataemia and renal phosphate wasting, produce a substance that causes hypophosphataemia in the cAMP content in OK cells. The tumour factor was between 8000 and 25 000 Daltons in size and was heat normal mouse of a normal-Hyp parabiotic pair [5,6,] .
Reversing the parabiosis normalizes serum phosphorus sensitive, suggesting that it might be a protein.
Parathyroid-hormone-like material was detected in in the normal mouse. The factor is not PTH, as parathyroidectomizing Hyp mice does not alter their the supernatants of the tumour cells with a two-site immunoradiometric assay. RPMI medium, or RPMI ability to produce hypophosphataemia in normal animals of a parabiotic pair. Nesbitt and others showed medium exposed to CHO cells, had some immunoreactivity, whereas the tumour cell conditioned medium that a normal kidney transplanted into a Hyp mouse, exhibits a reduced tubular maximum for phosphate contained twice as much PTH immunoreactivity. The material present in tumour cell supernatants was not [6 ] . Conversely, a Hyp mouse kidney transplanted in normal mouse ceases to waste phosphate in the urine. parathyroid hormone because, on serial dilution, the decrease in immunoreactivity did not parallel that Recently a mutant gene (PEX ) was isolated by the Hyp Consortium from patients with X-linked hypoobserved with authentic PTH. To test this further, the effects of a PTH receptor antagonist on the biological phosphataemic rickets [9 ] . The abnormal protein was not a phosphate transporter but was related to a family properties of the tumour factor or PTH were examined. The antagonist blocked the effect of PTH on phosphate of endopeptidases. It is very likely that the product encoded by this gene does not directly influence phostransport, but it did not block the effect of the tumour factor, suggesting once again that this molecule is not phate transport. It may, however, break down a normal circulating factor that causes hypophosphataemia. parathyroid hormone. PTH-RP was not detected in tumour cell supernatants. The tumour itself stained Thus the mutated gene might be responsible for the hypophosphataemia seen in these patients by allowing with anti-PTH antibodies. Since we found PTH immunoreactivity, we thought that the phosphate inhibitor an excess of this hypophosphataemic factor to circulate. might, in some way, be related to parathyroid hormone in structure.
In conclusion, there is persuasive evidence that a new factor, 'phosphatonin', may be responsible for the A tumour cDNA library was screened with PTH antibodies [4] . A clone ( Hem 1) which, in its longest alteration in phosphate transport seen in various diseases such as tumour-induced osteomalacia, X-linked open reading frame encoded a peptide that was 381 amino acids long, with a predicted molecular weight hypophosphataemia, and hypophosphataemia in the Hyp mouse and the gyroscopic mouse. 'Phosphatonin' of 42 000 Daltons, was isolated. The primary sequence of this peptide did not resemble PTH. The peptide did, may be abnormally low in patients with tumoural calcinosis, an unusual disease associated with elevated however, contain a protein kinase C activation domain similar to that of PTH. This is of some interest, as serum phosphorus, and 1,25-dihydroxyvitamin D concentrations, and ectopic deposition of calcium and PTH activates cellular processes by stimulating protein kinase A and protein kinase C. It may be that the phosphorus. 'Phosphatonin' may be appropriately elevated in patients with renal failure who have phos-PKC activation domain of this particular peptide is responsible for inhibiting phosphate transport. phate retention. The study of inhibitors of renal sodium phosphate transport and the characterization of these Expression of Hem 1 has not, however, resulted in the synthesis of a phosphate transport inhibitory peptide. factors will yield insights into the control of phosphate transport and balance. Some of the original tumour was implanted in nude mice, athymic mice, and serum phosphorus concentrations in these mice were monitored periodically over a period of several months. Serum phosphorus concen-References trations decreased in the mice in whom the tumour Information from the Hyp mouse and from patients
Introduction
The ATP-ubiquitin-proteasome proteolytic pathway
The turnover of protein in normal adults is enormous, averaging 280 g/day [1] , about 90% being intracellular The ATP-ubiquitin-proteasome pathway degrades as mammalian cells continually degrade and replace proteins by a novel mechanism and functions in the protein.
The degradative rates of cellular proteins vary nucleus and cytoplasm of all cells. Proteins degraded widely: some cytosolic enzymes have half-lives as short by this pathway are first 'marked' by covalent conjugaas 20 min while others last for days, and the majority tion to the small protein cofactor, ubiquitin, in a of rat hepatocyte proteins are replaced in days but in multistep process requiring three enzymes and ATP muscle or brain, the process takes weeks. Clearly, the ( Figure 1 ) [3 ] . After a chain of ubiquitin molecules is cell's proteolytic mechanisms must be highly selective added, the protein can be recognized by the large 26S and tightly regulated. If this were not true, uncontrolled proteasome complex in another ATP-dependent prodestruction of essential proteins or failure to degrade cess which releases ubiquitin for recycling. The proteoshort-lived regulatory proteins would drastically alter lytic core of this complex is the 20S particle consisting cell function. Dramatic increases in our understanding of two inner rings, each consisting of 7 beta-type of the mechanisms and regulation of protein degrada-subunits positioned between two outer rings, each tion have implications for treating human diseases. consisting of 7 alpha-type subunits [3] . After another Controlled destruction of cell proteins serves import-ATP-dependent reaction, which releases ubiquitin for ant homeostatic functions [1 ] : (1 ) rapid removal of recycling, the protein is unfolded and degraded by a rate-limiting enzymes and regulatory proteins is critical novel proteolytic mechanism utilizing threonine at the in controlling growth and metabolism (e.g. the pro-amino terminus of each beta-type subunit to catalyse grammed destruction of cyclins, the cell cycle regulatory cleavage of peptide bonds. This mechanism digests the proteins); (2 ) proteolysis allows cells to adapt to physio-entire protein to small peptides (i.e. a processive mechlogical conditions (e.g. during fasting, hepatic enzymes anism) which are rapidly degraded to amino acids by for glucose storage disappear while gluconeogenic cytoplasmic peptidases [3] . enzymes accumulate, but within hours of refeeding this How is the cell protected from the disaster of nonpattern reverses); (3 ) selective elimination of damaged specific proteolysis by this pathway? Selectivity or improperly folded proteins (e.g. after oxygen radical-depends on the ubiquitin conjugation process because damage or the mutated transmembrane regulator pro-cells contain a variety of ubiquitination enzymes that tein in cystic fibrosis; (4 ) proteolysis is required by the are specific for different types of proteins (e.g. specific immune system in its surveillance for cancer or virus-E2 and E3 enzymes combine to catalyse ubiquitination infected cells [2 ] ; (5) an inadequate diet or catabolic of the individual cyclins to regulate mitosis) [1, 3] . diseases stimulate the degradation of cell proteins to Second, the active sites of the 26S proteasome are provide amino acids for gluconeogenesis and protein isolated within its central chamber and only unfolded synthesis. In all these cases, the ATP-ubiquitin-pro-proteins can enter the narrow opening at the ends of teasome pathway plays a critical role.
the proteasome complex; unfolding requires recognition of the ubiquitin chain. These characteristics and ATP consumption at multiple steps provide a remarkCorrespondence and offprint requests to: W. E. Mitch MD, Renal able degree of selectivity, efficiency, and control of Division, Emory University School of Medicine, 1364 Clifton Road, Atlanta, GA 30322, USA.
protein degradation. The ubiquitin-proteasome pathway in disease of muscles [4] . In rats with acidosis from acute or states chronic uraemia (CRF ), there is increased muscle protein degradation and mRNAs encoding componIn catabolic illnesses, the loss of muscle results largely ents of the ubiquitin-proteasome pathway [1, 7] . In from accelerated breakdown of the long-lived, myofib-CRF, correcting acidosis blocks the accelerated proteorillar proteins (actin and myosin) which comprise lysis and prevents the rise in mRNAs of ubiquitin and 60-70% of muscle protein. In response to acidosis, proteasome subunits [7] . These findings point to coordinfection, or certain tumours, skeletal muscle protein inated adaptations that enhance the proteolytic capais lost preferentially while visceral organs (e.g. the city of the ubiquitin-proteasome pathway and favour kidney and liver) lose little or no protein, and the brain muscle wasting. is unaffected. Studies of rat muscles during fasting, In experimental models that mimic muscle-wasting acidosis, or denervation atrophy demonstrated that the conditions, there is consistent activation of the ATPloss of muscle is primarily due to activation of the dependent proteolytic pathway causing muscle protein ubiquitin-proteasome pathway [4, 5] . When atrophying breakdown [1 ] . Presumably this response evolved to muscles were incubated in vitro with agents that provide the injured or infected organism with amino blocked the activity of lysosomal or calcium-activated acids for energy and synthesis of new proteins (e.g. proteases (calpains), the accelerated proteolysis peracute-phase reactant proteins) but if prolonged, muscle sisted. However, inhibitors of ATP production reduced wasting occurs. For example, within hours of injecting muscle protein degradation to levels in control muscles.
endotoxin, or live bacteria, or puncture of the caecum, Increased levels of ubiquitin-conjugated proteins in the degradation of myofibrillar proteins by an ATPmuscles coincident with maximal protein degradation dependent process rises sharply [1, 8] . After thermal provided more definitive evidence for activation of the injury, protein catabolism increases markedly in ubiquitin-proteasome pathway [6 ] . There also were muscles distant from the injury and ATP-dependent increased levels of the mRNAs encoding ubiquitin and subunits of the proteasome during fasting, acidosis, proteolysis rises concurrently with ubiquitin mRNA [9 ] . The ubiquitin-proteasome pathway appears to be transcription factor, NF-kB and can exhibit potent anti-inflammatory effects in models of diseases [1] . responsible for muscle wasting in trauma patients, since mRNAs encoding components of the pathway Another therapeutic strategy would be to limit production or actions of factors initiating accelerated proteoare high in muscle biopsies [10 ] . Muscle wasting in cancer cannot be explained simply by anorexia, since lysis or to stimulate cellular programmes that conserve body proteins. Clearly, knowledge of the regulation tumour-bearing rats show greater muscle loss and higher rates of proteolysis compared to rats fed ident-and mechanisms of protein breakdown will provide insights into disease processes. ical amounts of food [11] . Again, cancer stimulates activity of the ATP-dependent proteolytic pathway and increases ubiquitin mRNA in muscle.
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The increased levels of mRNAs encoding ubiquitin and DK50740. and proteasome subunits in catabolic states suggest activation of a common genetic programme to enhance the expression of pathway components, and hence the References capacity of this degradative pathway. Recently nuclei were isolated from muscles of CRF or insulinopenic 1 . Mitch WE, Goldberg AL. Mechanisms of muscle wasting: the role of the ubiquitin-proteasome system. N Engl J Med (in press) rats and it was found that both conditions stimulate In denervated muscles, cellular events must signal cata- enzyme has been demonstrated. This question, howand also the development of methods for the reliable ever, remains unresolved and awaits the cloning of the measurement of vitamin D metabolites [1] and of 1a-hydroxylase when Northern or Western analysis parathyroid hormone (PTH ), led to a rapid increase will be available. Normal peripheral macrophages in our understanding of the pathophysiology of bone derived from monocytes synthesize calcitriol from and mineral metabolism in patients with renal disease.
25-hydroxyvitamin D 3 and in uraemia these macroInevitably the progress has also posed new questions phages show enhanced calcitriol production and and dilemmas. In the earlier years of renal replacement decreased catabolism [2] . A further non-renal 1a-therapy, hyperparathyroidism dominated the clinical hydroxylase has also been described in pig liver which picture, but now there is concern that our improving has a relatively high K m for 25-hydroxyvitamin D 3 ability to control hyperparathyroidism effectively has (17 mM as compared to 890 nM for the renal enzyme. led to the emergence of increasing numbers of patients
The K m of this liver enzyme in uraemic rats is inwith abnormally low bone turnover-adynamic or creased twofold, indicating decreased substrate aplastic bone disease. Because nutritional vitamin D affinity. In renal disease the reduction of total deficiency is also associated with low bone turnover, it 25-hydroxyvitamin D 3 -1a-hydroxylase activity in the is pertinent to re-examine the question of vitamin D kidney increases the proportionate contribution of deficiency in uraemia. Although it has been widely extrarenal calcitriol generation to total calcitriol assumed that replacement of the deficient hormone by production. means of alfacalcidol or calcitriol therapy is an appropriate substitute, the possibility that other vitamin D metabolites may also have an important role in the maintenance of normal bone metabolism must be
Actions of 25-hydroxyvitamin D 3
and calcitriol in considered.
uraemia Renal and non-renal production of calcitriol
Decreased calcitriol concentration leads to downregulation of the vitamin D receptor ( VDR) in the paraIn the untreated chronic renal failure (CRF ) patient, thyroid gland [3 ] and in other target tissues such as relative or absolute reduction of circulating calcitriol duodenum and there is evidence suggesting that this is concentration is invariable. The calcium homeostatic a translational or post-translational effect [4] . hormone, 1,25-dihydroxyvitamin D 3 (calcitriol ), is Downregulation of VDR would be expected to lead to formed in the kidney by 1a-hydroxylation of circulating decreased expression of calcitriol responsive genes; for 25-hydroxyvitamin D 3 . This hydroxylation is tightly example 24-hydroxylase activity is decreased by regulated by PTH, phosphate, ionized calcium and uraemia. The overall effect of these changes is to reduce calcitriol itself. 1a-hydroxylation of 25-the catabolism of 25-hydroxyvitamin D 3 . A number of hydroxyvitamin D 3 also occurs in a relatively unregu-low-molecular-weight components of uraemic serum lated manner at a number of extrarenal sites [2 ] . These have been shown to decrease VDR synthesis, decrease include sarcoid tissue, pulmonary alveolar macro-uptake of ligand bound VDR to the nucleus, reduce phages, and placenta. In conjunction with other parac-binding of ligand-bound VDR to DNA, and decrease rine factors, these tissues may under normal binding of ligand-bound VDR to the osteocalcin circumstances produce small quantities of calcitriol vitamin D response element ( VDRE ), and it is now necessary for local events.
clear that uraemia per se will lead to decreased expresWork in the early 1980s using embryonic bone cells sion of calcitriol-responsive genes [5 ] as well as inhibitsuggested the possibility that these cells could produce ing renal 1a-hydroxylase. In uraemia, 'normal' calcitriol levels may, therefore, still be insufficient to produce appropriate levels of calcitriol responsive gene in part be the explanation for end-organ resistance in found in patients who had been on haemodialysis for more than 1 year or with functioning transplants [8 ] . CRF [5 ] .
Both calcitriol and 25-hydroxyvitamin D 3 are carried Similar findings have been reported by other workers [9] [10] [11] contrib-influence of uraemia on diagnostic criteria (secondary hyperparathyroidism with elevated PTH and/or elevutes a significant part of the total 'vitamin D effect', and that this contribution is likely to be proportionately ated alkaline phosphatase and/or typical bone lesions) that would apply in non-uraemic subjects. In addition, greater in uraemia, when calcitriol concentration is low. 
How common is vitamin D deficiency in uraemia?
by questionable assay methodology in many of the early studies and by the necessity for arbitrary definiThis question presumes that we can first define tions of 'normality'. In the UK, the National External vitamin D deficiency. In statistical terms it could be, Quality Assurance Scheme has demonstrated wide and often is, defined as a plasma concentration of variations between the results obtained from different 25-hydroxyvitamin D that falls below the 95% confid-laboratories. It is important, therefore, that any claim ence limit (assuming a normal distribution of plasma that 25-hydroxyvitamin D 3 levels are lower than 25-hydroxyvitamin D concentration) in normal healthy normal must be assessed against the normal reported subjects. Published data suggest concentrations of range for the individual laboratory. 90±11 nmol/l, implying a lower limit of normal at It is not entirely clear why 25-hydroxyvitamin D 3 68 nmol/l. More relevant biologically, although not levels should be lower in renal disease except that adequately assessed, would be the concentration of lifestyle alteration and intercurrent illnesses may lead 25-hydroxyvitamin D below which the first signs of to lack of exposure to sunlight and decreased skin compensation (e.g. secondary hyperparathyroidism, production of the 25-hydroxyvitamin D 3 precursor. increasing calcitriol concentration or skeletal change) In patients with significant protein loss (nephrotic develop. This is likely to be substantially below syndrome or those on CAPD) a negative correlation 68 nmol/l in normals, and is unquantifiable in these has been demonstrated between serum 25-terms in uraemics where PTH is profoundly disturbed hydroxyvitamin D 3 and DBP in the dialysate and the for other reasons. degree of proteinuria [12 ] . A number of studies have suggested that reduction of 25-hydroxyvitamin D 3 is common in patients with
Consequences of vitamin D deficiency and response
uraemia. 25-hydroxyvitamin D 3 was measured in 22
to treatment patients with varying degrees of CRF (in some cases very advanced), and in seven of them concentrations comparable with those in non-CRF patients with Central to this issue is the possibility of biological actions specific to the various vitamin D metabolites. documented vitamin D deficiency osteomalacia were found [7 ] . The same group in 1979 reported low The presumption that all biological functions of vitamin D are subserved by calcitriol would, if correct, 25-hydroxyvitamin D 3 concentrations in patients with terminal renal failure and during the first year of render irrelevant concerns of vitamin D deficiencycalcitriol therapy given for standard indications should haemodialysis treatment, with normal concentrations
also, may have actions that differ qualitatively as well as quantitatively from calcitriol. For example in vitamin-D-deficient non-uraemic rats 25-hydroxyvitamin D 3
, but not calcitriol, increased References muscle phosphate content [13 ] . This metabolite also improving bone formation.
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The mechanisms underlying these differences remain 11 The pattern of lipid abnormality in dialysis patients without renal failure [5 ] . Similar results were obtained in both Southern and Northern European countries, The abnormalities of lipoprotein metabolism that are despite underlying differences in the susceptibility to associated with renal failure are not corrected by renal cardiovascular disease in the indigenous populations replacement therapy and may be manifested as hyperliof these regions. Furthermore, patients with an underpidaemia in the dialysis population [1 ] . Elevated lying diagnosis of diabetic nephropathy appear to be plasma triglyceride levels are found in between 30 and at 2 to 3 times greater risk than those with non-diabetic 70% of individuals undergoing maintenance dialysis renal disease. whilst hypercholesterolaemia, although less commonly
With the success of dialysis and renal transplantaobserved, is more likely to be present in patients tion, cardiovascular diseases including myocardial receiving CAPD [2 ] . Global measurement of plasma infarction, sudden death, cardiac failure, and stroke lipids tends to underestimate the size and scope of have become the leading cause of mortality in patients the problem since even when concentrations of total with chronic renal failure, collectively accounting for triglyceride and cholesterol levels fall within convenapproximately 50% of deaths in those who would have tional normal ranges, assessment of lipoprotein naturally succumbed to uraemia. Further efforts to profiles reveals accumulation of partially metabolized, prolong the lives of these individuals will need to take triglyceride-enriched very-low-density lipoprotein into account the risk factors that may contribute to ( VLDL) and intermediate-density lipoprotein (IDL) both vascular and myocardial disease. In addition to particles. In addition there may be a reduction in highhyperlipidaemia, these may include hypertension, gludensity lipoprotein ( HDL) and an increase in lipoprocose intolerance, hyperfibrinogenaemia, and elevated tein (a). Low-density lipoprotein (LDL) levels are plasma homocysteine levels [6 ] . normal or only modestly increased, although the composition and size of these particles may be altered.
The precise pathogenesis of these abnormalities is not fully understood, although impaired function of Lipid abnormalities and cardiovascular risk certain key enzymes including lipoprotein and hepatic triglyceride lipases appears to be important [1] . To date there have been no controlled clinical trials Longitudinal studies suggest that any changes associ-demonstrating that correction of deranged lipid metaated with peritoneal dialysis occur early in the course bolism in individuals receiving renal replacement of treatment and that lipoprotein abnormalities remain therapy protects against cardiovascular disease. otherwise stable over time on dialysis [3 ] . However, studies in the general population have established that lipid-lowering therapy leads to a reduction in both ischaemic cardiac events and mortality. Some
Cardiovascular risk in dialysis patients
nephrologists may be content to simply extrapolate these data to the high-risk group of patients under With the availability of a number of new lipid-lowering their care who arguably may benefit most from such drugs, nephrologists may now be in a position to offer treatment. Others may correctly point out that studies safe and effective therapy to correct the lipoprotein in non-renal populations have concentrated on the disturbances associated with uraemia [4] . However, consequences and management of hypercholesterolaemany will need to be convinced that such intervention mia resulting from elevated LDL levels, an abnormality is appropriate and that any benefits outweigh potential which is not a major feature of lipid disturbances risks. The most compelling argument in favour of complicating uraemia. Hypertriglyceridaemia, in contreatment is that patients receiving dialysis appear to trast, is not considered to be an independent risk factor be at particularly high risk of cardiovascular disease. and as such, has not become a primary target for This observation, originally made over 20 years ago, intervention. This approach may be misguided accordis supported by recent registry data demonstrating that ing to a recent study which suggested that elevated such individuals experience a 16-19-fold increased risk plasma triglyceride levels are a powerful predictor of of myocardial ischaemia and infarction when com-coronary disease risk if coincident with a high ratio of LDL to HDL cholesterol [7] . These observations imply that the pattern of lipoprotein disturbance present in such patients therapy aimed at lowering triglycerides Lipid lowing therapy in dialysis patients and LDL whilst restoring HDL levels to normal.
In an attempt to strengthen the case for treatment, Nephrologists who choose to treat lipid abnormalities a number of studies have examined the relationship in their dialysis patients may be reassured by a few between various lipid parameters and the presence of studies demonstrating the efficacy and safety of lipidclinically apparent atherosclerosis in individuals receiv-lowering drugs [4 ] . Such data should dispel early fears ing renal replacement therapy. Unfortunately many of that therapy would be associated with an unacceptably these trials have been cross-sectional in nature, includ-high incidence of side-effects in this population. Whilst ing only small numbers of patients, and have failed to dietary changes should not be neglected and optimal distinguish atherosclerosis-related events from other regimens still need to be established, 3-hydroxyforms of cardiovascular disease. In addition, many 3-metylglutaryl coenzyme A (HMG-CoA) reductase have failed to control for other risk factors and have inhibitors and fibric acid derivatives are proving to be assessed only total plasma lipid levels rather than the the most promising agents in the dialysis population. lipoprotein disturbances which characterize the Fibric acid derivatives are a logical choice because they uraemic dyslipidaemia. It is therefore not surprising enhance the activity of lipase enzymes that facilitate that the conclusions have been conflicting [6 ] . In the VLDL metabolism and can result in reduction in largest and longest study to date, 419 dialysis patients VLDL triglycerides of up to 50% and correction of were followed prospectively over a 21-year period low HDL levels [1 ] . Unlike clofibrate, newer drugs in during which time 49% died of cardiovascular disease this class do not accumulate in renal failure although and 23% experienced fatal or non-fatal ischaemic low starting doses are generally recommended. HMGevents. Smoking, hypertension, and hypertriglyceridae-CoA reductase inhibitors lower cholesterol by enhanmia were identified as independent risk factors for cing receptor-mediated clearance of LDL, particularly ischaemic cardiovascular disease in this population [8] . by the liver. Because elevated levels of this lipoprotein In contrast, several smaller cross-sectional studies have are not a prominent feature of the uraemic dyslipidaefailed to find an association between elevated triglycer-mia, the choice of this class of agent would appear less ide levels and complications resulting from vascular logical. However, HMG-CoA reductase inhibitors have disease [6 ] . Another recent prospective trial has identi-been reported to improve clearance of partially metafied elevated levels of lipoprotein (a) as an independent bolised VLDL 'remnant' particles. Whilst these agents predictor of clinical events attributable to atheroscler-may be particularly useful in the rarer patients who otic cardiovascular disease in patients receiving haemo-develop hypercholesterolaemia, looking beyond reductions in plasma lipids as the principal therapeutic goal, dialysis [9 ] . Furthermore, in a group of 196 uraemic they may well have an important impact on the lipoprodiabetics receiving haemodialysis, elevated cholesterol tein disturbances present in dialysis patients. Indeed levels with high LDL to HDL ratios were associated the precise targets of lipid-lowering therapy in such with an increased risk of cardiac death during a individuals still need to be clearly defined. For example, 45-month follow-up period. In this study, hypercholesthe benefits of cholesterol lowering may not be confined terolaemia was more common in the diabetics than in to patients with elevated baseline values in this high matched non-diabetic dialysed controls [10] . risk population.
Conclusion The patient on CAPD
Ideally, a controlled trial of lipid-lowering therapy in Glucose absorption from fluid and protein losses via dialysis patients is needed. Such a study will require a the peritoneum may help to explain the adverse impact large population randomized to receive either treatof peritoneal dialysis on lipid metabolism [2 ] . Whilst ment or placebo and long-term follow-up. Risk factors such patients are more likely to develop elevated other than lipid abnormalities will need to be controlled cholesterol levels, it is not known whether CAPD is for and clearly defined cardiac end-points assessed. associated with an increased incidence of cardiovas-Such a trial will become increasing difficult to conduct cular disease. In a longitudinal study, Avram et al. as nephrologists become uneasy about withholding examined lipid and lipoprotein levels in a large dialysis lipid-lowering therapy from their patients and logically population followed longitudinally over 2 or more conclude that abnormalities of lipid metabolism in the years [3 ] . Surprisingly, patients receiving CAPD who dialysis population represent a serious risk factor for died had lower plasma cholesterol and apo B levels progressive atherosclerosis. than survivors, exactly the opposite to what might be expected. Since cholesterol correlated directly with Introduction [5, 6] . Renal transplant patients are known to be at increased risk of cardiovascular disease. Since cardiovascular The lipid abnormality mortality is the leading cause of death in transplant recipients after the first year, it represents a major Hypercholesterolaemia, probably through the effect of threat for the long-term results of transplantation [1] .
oxidatively modified LDL, and elevation of Lp(a) are The search for risk factors for atherosclerotic cardioother established risk factors for atherosclerotic vascuvascular disease has challenged many investigators lar disease [7] [8] [9] . Even though these features do not during the past few decades. Numerous of these risk represent a part of the metabolic risk factor syndrome, factors are closely related to each other. Insulin resistthe induction of PAI-1 gene expression by oxidized ance seems to be a key feature of the most frequently LDL or Lp(a) and the observation that features of the observed disease entity associated with increased metabolic syndrome are present in subjects with small, cardiovascular morbidity in the industrialized world dense, cholesteryl ester depleted LDL particles [6 ] , [2 ] . This syndrome, described originally by Reaven as known to be more susceptible for oxidative modificasyndrome X [3 ] is called by many names, such as the tion [10] point towards a possible link between these 'syndrome of insulin resistance', the 'metabolic risk 'independent' risk factors and the metabolic risk factor factor syndrome', the 'metabolic syndrome', the syndrome. 'cardiovascular metabolic risk factor syndrome', etc.
Abnormalities in lipid and carbohydrate metabolism We prefer the name 'metabolic risk factor syndrome'. occur frequently in patients with chronic renal disease The classical features of this syndrome include obesity, [11, 12] . After renal transplantation, these abnormalitin particular a central one, insulin resistance and ies are even more pronounced. The currently used hyperinsulinaemia, with normal or impaired gluimmunosuppressive therapy with cyclosporin and cose tolerance and eventually manifest diabetes.
corticosteroids is generally considered to have an Hypertension and lipid abnormalities, in particular important contributory role in this regard [11 ] . elevation of the very-low-density lipoproteins ( VLDL) However, pretransplant lipid levels seem to have a and low levels of HDL cholesterol are other characterstrong correlation with post-transplant hyperlipidaeistics of this syndrome. As recently revealed, elevated mia [13] . Two years following transplantation, an levels of the major inhibitor of fibrinolysis, plasminincrease in total cholesterol, due to elevation of LDL ogen activator inhibitor type 1 (PAI-1) is another and HDL cholesterol but a decrease in VLDL cholesimportant part of the metabolic risk factor syndrome terol, and unchanged total and VLDL triglycerides [4 ] . Recent evidence suggests an important role of with a decrease in LDL triglycerides have been reported in patients on triple immunosuppression [14] . Insulin resistance is a feature frequently observed in patients
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with end-stage renal disease [12] . Both prednisolone Nephrol Dial Transplant ( 1997) 12: Editorial Comments 22 and cyclosporin are considered to be diabetogenic, and to be similar to that of 'naturally' occurring atherosclerosis [20 ] . at present more than 10% of cyclosporin/prednisolonetreated transplant recipients will develop posttransplant diabetes mellitus (PTDM ). A positive Hyperlipidaemia and chronic graft rejection family history of diabetes is more frequent in these patients, pointing towards the role of associated genetic factors [15] . Similarly to patients with NIDDM, insulin Evidence from both experimental and clinical studies resistance with hyperinsulinaemia and subsequent indicate a role of lipid abnormalities as important development of insulin deficiency are observed in contributors to the development and progression of patients with PTDM [16 ] .
CVR. In renal transplant patients with manifest CVR, hyperlipidaemia is more pronounced with a more atherogenic pattern compared with recipients with a
Abnormalities of the fibrinolytic system stable graft function [19] . Moreover, as it was recently shown in a prospective investigation, the development of histopathological changes compatible with CVR at Abnormalities of the fibrinolytic system are associated with increased cardiovascular morbidity [17] . An 6 months after transplantation, which in turn is an excellent predictor of subsequent late graft losses impaired fibrinolysis is present in two of three patients at 1 year following renal transplantation, possibly due [21, 22] , is associated with more pronounced lipid abnormalities already prior to transplantation. to prednisolone therapy [18 ] . The defective fibrinolysis, in the majority of the patients, is a consequence of Conversely such histopathological changes are also more frequent in patients with pretransplant hyperchoelevated levels of plasminogen activator inhibitor ( PAI-1 ), the specific inhibitor of the fibrinolytic system. lesterolaemia [23] . Hypercholesterolaemia both before [14] and after [22 ] renal transplantation were found In vitro, insulin as well as incubation with VLDL were shown to augment endothelial cell synthesis of PAI-1. to predict graft loss due to chronic rejection, while other studies could only identify hypertriglyceridaemia Hyperinsulinaemia as well as hypertriglyceridaemia are associated with elevated PAI-1 levels, and this may as an independent risk factor for chronic rejection [24 ] .
Patients who developed PTDM were found to have well be the link between defective fibrinolysis and the metabolic risk factor syndrome [4] .
an inferior graft survival at 5 years compared to patients without diabetes. Furthermore, extreme obesity was also found to be associated with an unfavour-
The metabolic syndrome and chronic graft rejection able graft outcome [25 ] .
In addition to the increased risk of cardiovascular
Fibrinolysis inhibitors and chronic graft rejection
disease, metabolic abnormalities were recently suggested to be involved in the pathogenesis and progression of chronic rejection, a major reason for late graft In a recent prospective study elevated PAI-1 levels were found in one-third of renal transplant recipients losses [19, 20] . The histopathological hallmark of chronic vascular rejection (CVR), vascular intimal before transplantation. Patients with elevated PAI-1 levels before transplantation were not different from hyperplasia, resembles early atherosclerotic lesions, which is the reason why this process is also called patients with normal PAI-1 levels with regard to age, BMI, lipid variables, original disease, or the time on transplant arteriosclerosis. The pathogenetic mechanisms of CVR in renal transplants have been suggested dialysis. However, at 2 years follow-up, they were more 1mmol/l; 2values are mean ± SD; 3mmol/l; 4ml/min; 5g/24 h. C-cr, endogenous creatinine clearance; CGD, chronic graft damage score in histological specimen.
obese, had lower HDL cholesterol levels and an inferior observed. However, patients with all features of the syndrome X present at 6 months post-transplant were glucose tolerance in addition to higher PAI-1 levels (unpublished observations).
different from patients without metabolic abnormalities before transplantation, i.e. during the phase of endElevated pretransplant PAI-1 activity was found to have prognostic value in the sense that it predicted an stage renal failure. Thus it seems reasonable to assume that the extent of metabolic abnormalities at 6 months unfavourable outcome with regard to early and late graft and patient loss. During a 3-year follow-up, a was not only a consequence of impaired graft function, and that pre-existing metabolic abnormalities could more than fivefold increase in the risk of graft loss was observed when PAI-1 activity was elevated prior to have contributed to a worse graft function at 6 months. transplantation. In those patients with a functioning graft at 6 months, histopathological features compatible with CVR were also more pronounced.
Summary
In summary, abnormalities in lipid and carbohydrate
The whole spectrum of the metabolic risk factor metabolism, including features of the metabolic risk syndrome and chronic graft rejection factor syndrome, are frequently present in patients both before and after renal transplantation. Risk factors of atherosclerosis may not only contribute to Patients presenting at 6 months after transplantation with the whole spectrum of the metabolic risk factor increased cardiovascular morbidity and mortality in this patient population, but can also be assumed to syndrome, including obesity, dyslipidaemia, impaired glucose tolerance or manifest NIDDM and/or hyperin-contribute to the development and progression of CVR and chronic graft dysfunction. sulinaemia with elevated PAI-1 levels and/or impaired fibrinolytic capacity were older and more overweight For preventing both early graft losses and the development of graft damage leading to late graft dysfuncand had more lipid abnormalities and higher PAI-1 levels before transplantation, compared to patients tion and graft loss, it appears to be essential to identify patients at risk early, prior to transplantation. without any of these metabolic risk factors at 6 months. Graft function at 6 months was worse in patients with Intervention aiming to reduce overweight, diet and exercise may be of benefit. The role of v-3 unsaturated the whole spectrum of the metabolic risk factor syndrome, and they also had histopathological changes fatty acid supplementation remains controversial.
Pharmacological intervention by antioxidants or agents compatible with CVR to a higher degree based on a higher CGD score on transplant biopsy. Graft outcome to reduce lipids and/or decrease PAI-1 synthesis may prove to be beneficial. Early identification of patients at 3 years post-transplant was different, with 5/12 grafts lost among these patients, while no graft losses at risk and intervention in due time may improve the results of renal transplantation. occurred in patients without metabolic risk factors at 6 months (unpublished observations).
